NASDAQ: CELZCreative Medical Technology Holdings Inc Stock
$4.35-0.12 (-2.68%)
Updated May 31, 2024
CELZ Price
$4.35
Fair Value Price
$2.44
Market Cap
$5.86M
52 Week Low
$3.93
52 Week High
$10.28
P/E
-1.16x
P/B
0.64x
P/S
822.86x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.00k
Earnings
-$5.28M
Gross Margin
60%
Operating Margin
-58,624.39%
Profit Margin
-58,624.4%
Debt to Equity
0.04
Operating Cash Flow
-$5M
Beta
0.01
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CELZ Overview
Creative Medical Technology Holdings, Inc. is a biotechnology company that focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. Offerings include CaverStem to treat erectile dysfunction, FemCelz for the treatment of loss of genital sensitivity and dryness, StemSpine to treat chronic lower back pain, ImmCelz for the treatment of stroke patients, and OvaStem for treatment of female infertility. Creative Medical Technology was founded in 1998 and is based in Phoenix, AZ.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CELZ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CELZ ($4.35) is overvalued by 78.1% relative to our estimate of its Fair Value price of $2.44 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CELZ ($4.35) is not significantly undervalued (78.1%) relative to our estimate of its Fair Value price of $2.44 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CELZ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CELZ due diligence checks available for Premium users.
Be the first to know about important CELZ news, forecast changes, insider trades & much more!
CELZ News
Valuation
CELZ fair value
Fair Value of CELZ stock based on Discounted Cash Flow (DCF)
Price
$4.35
Fair Value
$2.44
Overvalued by
78.10%
CELZ ($4.35) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CELZ ($4.35) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CELZ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CELZ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.16x
Industry
-14.17x
Market
28.44x
CELZ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.64x
Industry
6.04x
CELZ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CELZ's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.0M
Profit Margin
0%
CELZ's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CELZ's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.6M
Liabilities
$391.0k
Debt to equity
0.04
CELZ's short-term assets ($9.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CELZ's short-term assets ($9.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CELZ's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CELZ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$896.9k
Investing
$6.5M
Financing
-$82.8k
CELZ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CELZ vs Biotech Stocks
Creative Medical Technology Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.